CancerNHS-GalleriNCT05611632
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
A study testing Multi-cancer early detection test (Galleri test) in people with Cancer, run by GRAIL, Inc. at 1 site in United Kingdom.
Trial summary
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers. The trial aims to see if using the Galleri test alongside standard cancer testing in the NHS can help to find cancers at an early stage when they are… Read more about this study
- Who is it for?
- Ages 50 to 77 yearsHealthy volunteers can take part
- Conditions the study is for
- Cancer
- What is being tested?
- Multi-cancer early detection test (Galleri test)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 142,318 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 31 Aug 2021to Jan 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 77 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants must be at 50-77 years of age, inclusive, at the time of data extraction from NHS datasets or GP records used to identify potential participants; and
- Capable of giving signed and legally effective informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. Consent provided by a legally authorised representative is not permitted in this protocol.
Who cannot join
- Previous or current participation in another GRAIL-sponsored study.
- Personal history of invasive cancer or haematologic malignancy, diagnosed within the three years prior to expected enrolment date. Note: Individuals with a diagnosis of non-melanoma skin cancer and prostate cancer patients whose only treatment is active surveillance are NOT excluded
- Definitive treatment for invasive cancer or haematologic malignancy within the 3 years prior to expected enrolment date, including adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer).
- Currently taking demethylating or cytotoxic agents for any condition.
- Undergoing current investigation for suspected cancer, defined as having been referred to a two week wait clinic or undergoing investigations at an RDC or other clinic with a stated suspicion of cancer.
- Currently on a palliative care pathway.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Controlled Trial to Assess the Clinical Utility of a Multi-cancer Early Detection (MCED) Test for Population Screening in the United Kingdom (UK) When Added to Standard of Care
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers. The trial aims to see if using the Galleri test alongside standard cancer testing in the NHS can help to find cancers at an early stage when they are easier to treat.
The trial has enrolled approximately 140,000 participants who will be actively followed for approximately three years from the date of enrollment.
Read the detailed description
This is a prospective, randomized, controlled trial to assess the performance and clinical utility of a multi-cancer early detection test for population screening in the UK when added to standard of care. Participants and the study teams remain blinded throughout the study with the exception of the study nurses returning the results and a small number of staff to enable them to perform administrative duties. Blinding is maintained for participants with the exception of those participants who test positive. Those who test positive will be informed by designated trial staff and will be referred for standard of care investigations and treatment. Trial sponsor employees, the CIs and site staff (unless identified differently in the blinding plan for study conduct needs) will remain blinded throughout the study.
Randomization will be to either the intervention arm, with blood collection and evaluation of the test with consequent investigation and treatment of a positive test through referral to the NHS urgent two week wait pathway, or to the control arm, where blood samples are collected at designated intervals and will be stored for potential future evaluation, but participants do not receive test results and otherwise continue to receive routine NHS care.
Unless diagnosed with cancer, participants in both arms will be asked to return for annual visits at approximately 12 and 24 months. All participants whether test positive, test negative or not tested will be followed for cancer and associated outcomes via NHS dataset linkages.
- Conditions
- Cancer
- Being tested
- Multi-cancer early detection test (Galleri test)
- Keywords
- multi-cancer early detection, cancer screening, MCED, circulating cell-free tumor DNA
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multi-cancer early detection test (Galleri test)Device
Also called Galleri test
Blood collection and multi cancer early detection testing with return of positive test results.
| Study group | Role | What they receive |
|---|---|---|
| Interventional | Experimental | Blood collection and multi-cancer early detection testing with return of positive test results. Receives: Device: Multi-cancer early detection test (Galleri test) |
| Control | No intervention | Blood collection only. |
What is being measured
The primary outcome is the main question the study is designed to answer.
incidence of stage III and IV cancers diagnosed in the intervention arm as compared with the control arm
using a fixed-sequence statistical strategy as below:
- first, evaluate for a statistically significant difference in a prespecified group of primary cancer types: lung, head \& neck, colorectal, pancreas, myeloma/plasma cell neoplasm, liver/bile duct, stomach, oesophagus, anus, lymphoma, ovary, and bladder.
- if a statistically significant reduction in absolute numbers is found, continue by evaluating for a difference in all cancer types excluding prostate cancer.
- If the above evaluations are both significant, evaluate for a difference in all cancer types.
Measured: 3-4 years after randomization
Secondary outcomes (17)
incidence of advanced cancers (stage III and IV cancers or one that results in a cancer-specific death) diagnosed in the intervention arm as compared with the control arm.
Measured: 3-4 years after randomization
incidence of stage IV cancers diagnosed in the intervention arm as compared with the control arm
sequentially:
- for a prespecified group of 12 cancer types: lung, head \& neck, colorectal, pancreas, myeloma/plasma cell neoplasm, liver/bile duct, stomach, esophagus, anus, lymphoma, ovary, and bladder.
- for all cancer types excluding prostate cancer.
- for all cancer types.
Measured: 1 year after randomization
incidence of all cancers diagnosed in the intervention arm as compared with the control arm
Measured: 1 year after randomization
incidence of stage IV cancers following the second blood draw and 12 months of follow-up, with prevalent cases excluded
Measured: 2 years after randomization
incidence of stage IV cancers diagnosed in the intervention arm as compared with the control arm.
sequentially:
- for a prespecified group of 12 cancer types: lung, head \& neck, colorectal, pancreas, myeloma/plasma cell neoplasm, liver/bile duct, stomach, esophagus, anus, lymphoma, ovary, and bladder.
- for all cancer types excluding prostate cancer.
- for all cancer types.
Measured: 3-4 years after randomization
modelled cancer mortality at 7 years post-randomization based on cancers diagnosed within 3-4 years after randomization in the intervention arm as compared with the control arm.
Measured: 3-4 years after randomization
stage distribution by cancer type for the two arms.
Measured: 3-4 years after randomization
incidence of stage III and IV cancers excluding breast, cervical, and colorectal diagnosed in the intervention arm as compared with the control arm.
Measured: 3-4 years after randomization
incidence of stage III/ IV cancers following the third blood draw.
Measured: 3-4 years after randomization
overdiagnosis by comparing the cumulative number of cancers diagnosed within 3-4 years of randomisation in individuals with a positive baseline test (evaluated retrospectively in the control arm) between arms.
Measured: 3-4 years after randomization
cancer-specific mortality in the intervention arm as compared with the control arm.
specifically:
- nested cancer-specific mortality up to 5 years after randomization.
- cancer-specific mortality (up to 5 years and) up to 8 years after randomization.
Measured: up to 8 years after randomization
proportion of stage I and II cancers in the intervention arm as compared with the control arm in the third screening round.
Measured: 3-4 years after randomization
test performance (sensitivity, specificity, positive predictive value, negative predictive value) and cancer signal origin accuracy) in the intervention arm.
Measured: Up to 3 years after randomization
participant-reported psychological impact including anxiety, at various timepoints in all test positive cases.
Measured: Up to 1 year after randomization
number and type of invasive procedures performed, and complications and deaths associated with follow-up diagnostic procedures in all test positive cases.
Measured: Up to 3 years after randomization
radiation exposure by participants associated with follow-up diagnostic procedures following a positive MCED test result.
Measured: Up to 3 years after randomization
use of the MCED test across three annual timepoints on healthcare resource utilization for cancer diagnosis and treatment.
Measured: Up to 3 years after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2022
- Study start31 Aug 2021
- Primary completion12 Jun 2026
- Study completionJan 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomised to either the intervention arm, with blood collection and evaluation of the test with consequent investigation and treatment of a positive test through referral to the NHS urgent two week wait pathway, or to the control arm, where blood samples are collected at designated intervals and will be stored for potential future evaluation, but participants do not receive test results and otherwise continue to receive routine NHS care.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 142,318 participants (actual)
Sponsor and investigators
- Lead sponsor
- GRAIL, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- The Cancer Research UK Cancer Prevention Trials Unit at Queen Mary University of London (CPTU)
- Responsible party
- Sponsor
- Investigators
- Harpal Kumar, Study director, GRAIL, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05611632
- Sponsor's protocol ID
- GRAIL-009
- Other IDs
- ISRCTN91431511
- Acronym
- NHS-Galleri
- Status last verified
- Jul 2026
- First submitted
- 28 Oct 2022
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Marlow LAV, Schmeising-Barnes N, Warwick J, Waller J. Psychological Impact of the Galleri test (sIG(n)al): protocol for a longitudinal evaluation of the psychological impact of receiving a cancer signal in the NHS-Galleri trial. BMJ Open. 2023 Jul 21;13(7):e072657. doi: 10.1136/bmjopen-2023-072657.
PubMed 37479515Neal RD, Johnson P, Clarke CA, Hamilton SA, Zhang N, Kumar H, Swanton C, Sasieni P. Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. Cancers (Basel). 2022 Oct 1;14(19):4818. doi: 10.3390/cancers14194818.
PubMed 36230741Brentnall AR, Mathews C, Beare S, Ching J, Sleeth M, Sasieni P. Dynamic data-enabled stratified sampling for trial invitations with application in NHS-Galleri. Clin Trials. 2023 Aug;20(4):425-433. doi: 10.1177/17407745231167369. Epub 2023 Apr 24.
PubMed 37095697Sasieni P, Johnson P, Round T, Warwick J, Jones H, Dolly S, Lee L, Lee Y, Kumar H, Liang W, Smittenaar R, Neal RD, Swanton C. Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis. N Engl J Med. 2026 Sep 22. doi: 10.1056/NEJMoa2505723. Online ahead of print.
PubMed 42776074Neal RD, Dolly S, Johnson P, Jones H, Kumar SH, Lee LYW, Lee Y, Liang W, Round T, Smittenaar R, Warwick J, Sasieni P, Swanton C. Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial. Nat Med. 2026 Sep 22. doi: 10.1038/s41591-026-04652-8. Online ahead of print.
PubMed 42773209Marlow LAV, Schmeising-Barnes N, Waller J. Experience of NHS diagnostic investigation following a multi-cancer early detection (MCED) screening test: qualitative interviews with NHS-Galleri trial participants who had a cancer signal detected. EClinicalMedicine. 2026 Jan 8;91:103733. doi: 10.1016/j.eclinm.2025.103733. eCollection 2026 Jan.
PubMed 41567711Swanton C, Bachtiar V, Mathews C, Brentnall AR, Lowenhoff I, Waller J, Bomb M, McPhail S, Pinches H, Smittenaar R, Hiom S, Neal RD, Sasieni P. NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants. Clin Trials. 2025 Apr;22(2):227-238. doi: 10.1177/17407745241302477. Epub 2025 Jan 25.
PubMed 39862108Smittenaar R, Quaife SL, von Wagner C, Higgins T, Hubbell E, Lee L. Impact of screening participation on modelled mortality benefits of a multi-cancer early detection test by socioeconomic group in England. J Epidemiol Community Health. 2024 May 9;78(6):345-353. doi: 10.1136/jech-2023-220834.
PubMed 38429085
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Controlled Trial to Assess the Clinical Utility of a Multi-cancer Early Detection (MCED) Test for Population Screening in the United Kingdom (UK) When Added to Standard of Care
- ClinicalTrials.gov ID
- NCT05611632
- Acronym / sponsor ID
- NHS-Galleri / GRAIL-009
- Conditions
- Cancer
- Keywords
- multi-cancer early detection, cancer screening, MCED, circulating cell-free tumor DNA
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 142,318 participants (actual)
- Lead sponsor
- GRAIL, Inc.Industry (pharma, biotech, devices)
- Collaborators
- The Cancer Research UK Cancer Prevention Trials Unit at Queen Mary University of London (CPTU)
- Study start
- 31 Aug 2021 (actual)
- Primary completion
- 12 Jun 2026 (actual)
- Study completion
- Jan 2031 (estimated)
- First posted
- 10 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers. The trial aims to see if using the Galleri test alongside standard cancer testing in the NHS can help to find cancers at an early stage when they are easier to treat.
The trial has enrolled approximately 140,000 participants who will be actively followed for approximately three years from the date of enrollment.
Detailed description
This is a prospective, randomized, controlled trial to assess the performance and clinical utility of a multi-cancer early detection test for population screening in the UK when added to standard of care. Participants and the study teams remain blinded throughout the study with the exception of the study nurses returning the results and a small number of staff to enable them to perform administrative duties. Blinding is maintained for participants with the exception of those participants who test positive. Those who test positive will be informed by designated trial staff and will be referred for standard of care investigations and treatment. Trial sponsor employees, the CIs and site staff (unless identified differently in the blinding plan for study conduct needs) will remain blinded throughout the study.
Randomization will be to either the intervention arm, with blood collection and evaluation of the test with consequent investigation and treatment of a positive test through referral to the NHS urgent two week wait pathway, or to the control arm, where blood samples are collected at designated intervals and will be stored for potential future evaluation, but participants do not receive test results and otherwise continue to receive routine NHS care.
Unless diagnosed with cancer, participants in both arms will be asked to return for annual visits at approximately 12 and 24 months. All participants whether test positive, test negative or not tested will be followed for cancer and associated outcomes via NHS dataset linkages.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will be randomised to either the intervention arm, with blood collection and evaluation of the test with consequent investigation and treatment of a positive test through referral to the NHS urgent two week wait pathway, or to the control arm, where blood samples are collected at designated intervals and will be stored for potential future evaluation, but participants do not receive test results and otherwise continue to receive routine NHS care.
| Arm | Type | Receives |
|---|---|---|
| Interventional | Experimental | Device: Multi-cancer early detection test (Galleri test)Blood collection and multi-cancer early detection testing with return of positive test results. |
| Control | No intervention | –Blood collection only. |
Who may qualify
- Ages
- 50 to 77 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Participants must be at 50-77 years of age, inclusive, at the time of data extraction from NHS datasets or GP records used to identify potential participants; and
- Capable of giving signed and legally effective informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. Consent provided by a legally authorised representative is not permitted in this protocol.
Key exclusion criteria (6 listed)
- Previous or current participation in another GRAIL-sponsored study.
- Personal history of invasive cancer or haematologic malignancy, diagnosed within the three years prior to expected enrolment date. Note: Individuals with a diagnosis of non-melanoma skin cancer and prostate cancer patients whose only treatment is active surveillance are NOT excluded
- Definitive treatment for invasive cancer or haematologic malignancy within the 3 years prior to expected enrolment date, including adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer).
- Currently taking demethylating or cytotoxic agents for any condition.
- Undergoing current investigation for suspected cancer, defined as having been referred to a two week wait clinic or undergoing investigations at an RDC or other clinic with a stated suspicion of cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multi-cancer early detection test (Galleri test)Also: Galleri testBlood collection and multi cancer early detection testing with return of positive test results. | Device | Interventional |
Primary outcome
incidence of stage III and IV cancers diagnosed in the intervention arm as compared with the control arm
Time frame: 3-4 years after randomization
using a fixed-sequence statistical strategy as below: * first, evaluate for a statistically significant difference in a prespecified group of primary cancer types: lung, head \& neck, colorectal, pancreas, myeloma/plasma cell neoplasm, liver/bile duct, stomach, oesophagus, anus, lymphoma, ovary, and bladder. * if a statistically significant reduction in absolute numbers is found, continue by evaluating for a difference in all cancer types excluding prostate cancer. * If the above evaluations are both significant, evaluate for a difference in all cancer types.
17 secondary outcomes
incidence of advanced cancers (stage III and IV cancers or one that results in a cancer-specific death) diagnosed in the intervention arm as compared with the control arm.
Time frame: 3-4 years after randomization
incidence of stage IV cancers diagnosed in the intervention arm as compared with the control arm
Time frame: 1 year after randomization
incidence of all cancers diagnosed in the intervention arm as compared with the control arm
Time frame: 1 year after randomization
incidence of stage IV cancers following the second blood draw and 12 months of follow-up, with prevalent cases excluded
Time frame: 2 years after randomization
incidence of stage IV cancers diagnosed in the intervention arm as compared with the control arm.
Time frame: 3-4 years after randomization
modelled cancer mortality at 7 years post-randomization based on cancers diagnosed within 3-4 years after randomization in the intervention arm as compared with the control arm.
Time frame: 3-4 years after randomization
stage distribution by cancer type for the two arms.
Time frame: 3-4 years after randomization
incidence of stage III and IV cancers excluding breast, cervical, and colorectal diagnosed in the intervention arm as compared with the control arm.
Time frame: 3-4 years after randomization
incidence of stage III/ IV cancers following the third blood draw.
Time frame: 3-4 years after randomization
overdiagnosis by comparing the cumulative number of cancers diagnosed within 3-4 years of randomisation in individuals with a positive baseline test (evaluated retrospectively in the control arm) between arms.
Time frame: 3-4 years after randomization
cancer-specific mortality in the intervention arm as compared with the control arm.
Time frame: up to 8 years after randomization
proportion of stage I and II cancers in the intervention arm as compared with the control arm in the third screening round.
Time frame: 3-4 years after randomization
test performance (sensitivity, specificity, positive predictive value, negative predictive value) and cancer signal origin accuracy) in the intervention arm.
Time frame: Up to 3 years after randomization
participant-reported psychological impact including anxiety, at various timepoints in all test positive cases.
Time frame: Up to 1 year after randomization
number and type of invasive procedures performed, and complications and deaths associated with follow-up diagnostic procedures in all test positive cases.
Time frame: Up to 3 years after randomization
radiation exposure by participants associated with follow-up diagnostic procedures following a positive MCED test result.
Time frame: Up to 3 years after randomization
use of the MCED test across three annual timepoints on healthcare resource utilization for cancer diagnosis and treatment.
Time frame: Up to 3 years after randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Background: PubMed 37479515Marlow LAV, Schmeising-Barnes N, Warwick J, Waller J. Psychological Impact of the Galleri test (sIG(n)al): protocol for a longitudinal evaluation of the psychological impact of receiving a cancer signal in the NHS-Galleri trial. BMJ Open. 2023 Jul 21;13(7):e072657. doi: 10.1136/bmjopen-2023-072657.
- Background: PubMed 36230741Neal RD, Johnson P, Clarke CA, Hamilton SA, Zhang N, Kumar H, Swanton C, Sasieni P. Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. Cancers (Basel). 2022 Oct 1;14(19):4818. doi: 10.3390/cancers14194818.
- Background: PubMed 37095697Brentnall AR, Mathews C, Beare S, Ching J, Sleeth M, Sasieni P. Dynamic data-enabled stratified sampling for trial invitations with application in NHS-Galleri. Clin Trials. 2023 Aug;20(4):425-433. doi: 10.1177/17407745231167369. Epub 2023 Apr 24.
- Derived from this study: PubMed 42776074Sasieni P, Johnson P, Round T, Warwick J, Jones H, Dolly S, Lee L, Lee Y, Kumar H, Liang W, Smittenaar R, Neal RD, Swanton C. Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis. N Engl J Med. 2026 Sep 22. doi: 10.1056/NEJMoa2505723. Online ahead of print.
- Derived from this study: PubMed 42773209Neal RD, Dolly S, Johnson P, Jones H, Kumar SH, Lee LYW, Lee Y, Liang W, Round T, Smittenaar R, Warwick J, Sasieni P, Swanton C. Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial. Nat Med. 2026 Sep 22. doi: 10.1038/s41591-026-04652-8. Online ahead of print.
- Derived from this study: PubMed 41567711Marlow LAV, Schmeising-Barnes N, Waller J. Experience of NHS diagnostic investigation following a multi-cancer early detection (MCED) screening test: qualitative interviews with NHS-Galleri trial participants who had a cancer signal detected. EClinicalMedicine. 2026 Jan 8;91:103733. doi: 10.1016/j.eclinm.2025.103733. eCollection 2026 Jan.
- Derived from this study: PubMed 39862108Swanton C, Bachtiar V, Mathews C, Brentnall AR, Lowenhoff I, Waller J, Bomb M, McPhail S, Pinches H, Smittenaar R, Hiom S, Neal RD, Sasieni P. NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants. Clin Trials. 2025 Apr;22(2):227-238. doi: 10.1177/17407745241302477. Epub 2025 Jan 25.
- Derived from this study: PubMed 38429085Smittenaar R, Quaife SL, von Wagner C, Higgins T, Hubbell E, Lee L. Impact of screening participation on modelled mortality benefits of a multi-cancer early detection test by socioeconomic group in England. J Epidemiol Community Health. 2024 May 9;78(6):345-353. doi: 10.1136/jech-2023-220834.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingPhase 1/2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
RecruitingPhase 3
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Ovarian Cancer, Ovarian Neoplasms
RecruitingPhase 1/2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Lymphoma, Non-Hodgkin Lymphoma
RecruitingPhase 3
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Harpal Kumar study director
GRAIL, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multi-cancer early detection test (Galleri test) in people with Cancer, run by GRAIL, Inc. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
incidence of stage III and IV cancers diagnosed in the intervention arm as compared with the control arm (time frame: 3-4 years after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05611632, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.